Welcome to our dedicated page for HEARTFLOW SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Heartflow, Inc. (Nasdaq: HTFL), a medical technology company that applies artificial intelligence to coronary computed tomography angiography (CTA) for non-invasive coronary artery disease detection and management. Investors can review the company’s periodic and current reports to understand its financial condition, risk factors, and key operational developments.
Heartflow’s Form 10-K annual reports and Form 10-Q quarterly reports describe its business as a commercial-stage provider of non-invasive CAD detection solutions built around the Heartflow One platform, including FFRCT Analysis and Plaque Analysis. These filings typically discuss revenue sources, geographic operations in regions such as the United States, the United Kingdom, Japan, and the rest of Europe, and the company’s status as an emerging growth company listed on the Nasdaq Global Select Market.
Form 8-K current reports offer more immediate updates on material events, such as financial results releases, participation in financing transactions, or changes to credit agreements. For example, Heartflow has used Form 8-K to furnish earnings press releases and to disclose the prepayment and termination of a prior credit agreement following its initial public offering.
Through this page, users can also locate proxy statements and executive compensation disclosures, as well as Form 4 insider transaction reports when applicable. Stock Titan enhances these filings with AI-powered summaries that explain complex sections, highlight important risk disclosures, and clarify how Heartflow’s CAD-focused health information services and AI technologies are reflected in its regulatory reporting. Real-time updates from the SEC’s EDGAR system ensure that new HTFL filings, including 10-Ks, 10-Qs, 8-Ks, and ownership reports, are available promptly for detailed review.
HTFL filed a Form 144/A notice for a planned sale of up to 8,000 shares of its common stock through Fidelity Brokerage Services LLC on or about February 5, 2026 on NASDAQ. The aggregate market value of the planned sale is listed as 218,560.00.
The seller acquired 6,849 shares on June 15, 2024 and 1,151 shares on December 17, 2024 through stock option exercises from the issuer, paying cash in each case. Shares outstanding were 85,158,719 at the time referenced.
An affiliate of HTFL has filed a Rule 144 notice to sell 65,153 shares of common stock through Fidelity on the NASDAQ, with an aggregate market value of 1,595,485.25. The issuer had 85,158,719 shares outstanding at the time of the notice.
The shares to be sold were acquired over several years via stock option exercises, restricted stock vesting, and a prior option grant, with acquisition dates ranging from 2018 to 2026. The seller certified they are not aware of any undisclosed material adverse information about the issuer.
HeartFlow, Inc. Chief Accounting Officer and VP Marie L. Jones reported routine equity compensation and related tax withholding transactions. On February 6, 2026, she received 37,795 stock options with an exercise price of $27.74 per share, and 21,629 restricted stock units that vest quarterly over four years, starting from that date.
The filing also shows 94 shares of common stock were withheld by HeartFlow to cover income tax obligations from previously granted RSUs that vested, at a price of $27.74 per share. After these transactions, she directly owns 31,650 shares of common stock and 37,795 stock options.
Heartflow, Inc. CEO John C.M. Farquhar reported multiple equity transactions. On February 6, 2026, he was granted 183,850 restricted stock units at no cost, vesting in equal quarterly installments over four years starting on that date. The same day, 1,541 shares of common stock were withheld by the company to cover taxes tied to previously reported RSU vesting.
Also on February 6, 2026, he received a stock option for 321,259 shares at an exercise price of $27.74 per share, vesting in equal monthly installments over four years. On February 10, 2026, he sold 22,562 shares of common stock at a weighted average price of $27.46 under a Rule 10b5-1 trading plan, and reported owning 591,656 common shares and 321,259 options directly after these transactions.
HeartFlow, Inc.'s Chief Medical Officer, Campbell Rogers, reported new equity awards and related share activity. On February 6, 2026, he received a stock option covering 94,488 shares of common stock with a $27.74 exercise price, vesting monthly over four years starting from the vesting commencement date.
On the same date, he was granted 54,073 restricted stock units, which vest in 16 equal quarterly installments beginning February 6, 2026, subject to continued service. The filing also shows 515 shares of common stock withheld at $27.74 per share to cover tax obligations upon RSU vesting, and reports additional indirect common stock holdings through several trusts.
Heartflow, Inc. Chief Financial Officer Verghese Vikram received new equity awards and had shares withheld for taxes. On February 6, 2026, he was granted a stock option for 119,685 shares of common stock at an exercise price of $27.74 per share, vesting in 1/48 increments monthly from the vesting commencement date.
He also received 68,493 restricted stock units that begin vesting on February 6, 2026, with 1/16 of the RSUs vesting on each quarterly anniversary, contingent on continued service. In connection with the vesting and net settlement of previously reported RSUs, 542 shares of common stock were retained by Heartflow to satisfy income tax withholding obligations. Following these transactions, he directly beneficially owned 212,863 shares of common stock and 119,685 stock options.
HTFL has a shareholder who filed a Form 144 notice to sell 22,562 common shares through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of $619,556.99. The issuer has 85,158,719 shares outstanding.
The shares to be sold were acquired on 06/25/2024 via a stock option exercise paid in cash, and the approximate sale date listed is 02/10/2026.
Wellington Management Group LLP and related entities report beneficial ownership of 5,894,070 shares of Heartflow, Inc. common stock, representing 6.9% of the class as of 12/31/2025. The shares are held of record by clients of various Wellington investment advisers.
Wellington has shared voting power over 5,877,783 shares and shared dispositive power over 5,894,070 shares, with no sole voting or dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Heartflow.
Heartflow, Inc. director Julie A. Cullivan reported a planned stock sale. On February 5, 2026, she sold 8,000 shares of Common Stock of Heartflow at $27.32 per share, in an open-market transaction.
The filing states this trade was carried out under a pre-arranged Rule 10b5-1 trading plan that she adopted on September 12, 2025. After the sale, she continued to hold 36,413 shares of Heartflow common stock in direct ownership.
BCLS Fund III Investments, LP, a Bain Capital Life Sciences affiliated fund and 10% owner of Heartflow, Inc., reported a sale of 2,000,000 shares of Heartflow common stock on February 4, 2026 at $28.05 per share. After this transaction, BCLS Fund III Investments indirectly held 10,448,158 shares of Heartflow common stock. Related Bain Capital Life Sciences entities may be deemed to share voting and dispositive power over these securities and each disclaims beneficial ownership except to the extent of its pecuniary interest.
FAQ
What is the current stock price of HEARTFLOW (HTFL)?
What is the market cap of HEARTFLOW (HTFL)?
